Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | POLB | P06746 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29853676 | 1.00 | SMN1; SMN2 (0.79) | SMN1; SMN2POLBKDM4ECYP1A2CYP2D6 | |
| SCHEMBL26768695 | 0.91 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBKDM4ECYP1A2CYP2D6 | |
| SCHEMBL30629168 | 0.91 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBKDM4ECYP1A2CYP2D6 | |
| SCHEMBL29853687 | 0.91 | KDM4E (0.71) | SMN1; SMN2POLBKDM4ECYP1A2CYP2D6 | |
| SCHEMBL5150983 | 0.89 | SMN1; SMN2 (0.66) | SMN1; SMN2POLBKDM4ECYP2D6CYP2C9 | |
| SCHEMBL26768653 | 0.89 | SMN1; SMN2 (1.00) | SMN1; SMN2POLBKDM4ECYP1A2CYP2D6 | |
| SCHEMBL26785564 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2POLBKDM4ECYP1A2CYP2D6 | |
| SCHEMBL29853683 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2POLBKDM4ECYP1A2CYP2D6 | |
| SCHEMBL5342329 | 0.87 | SMN1; SMN2 (0.84) | SMN1; SMN2POLBKDM4ECYP1A2CYP2D6 | |
| SCHEMBL6536172 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2POLBKDM4ECYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-15 | — | — | US | disclosed |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-08 | — | — | US | disclosed |
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | VANDRIA SA (CH) | 2024-12-26 | — | — | US | disclosed |
| US-20240158363-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | AMAZENTIS SA (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20240158364-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | AMAZENTIS SA (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20240158365-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | AMAZENTIS SA (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20240139149-A1 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | VANDRIA SA (CH) | 2024-05-02 | — | — | US | disclosed |
| WO-2024025953-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | VANDRIA SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| EP-4284781-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | Vandria SA (CH) | 2023-12-06 | — | — | EP | disclosed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
| CN-117015530-A | Urolithin derivatives and methods of use thereof | 范徳利亚股份公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20220259173-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | SPIROCHEM AG (CH) | 2022-08-18 | — | — | US | disclosed |
| WO-2022162471-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | VANDRIA SA (CH) | 2022-08-04 | — | — | WO | disclosed |
| US-20200261861-A1 | SELECTIVELY PERMEABLE GRAPHENE OXIDE MEMBRANE | NITTO DENKO CORPORATION (JP) | 2020-08-20 | — | — | US | disclosed |
| EP-0788526-B1 | NEGATIVE BIREFRINGENT RIGID ROD POLYMER FILMS | UNIV AKRON (US) | 2003-08-20 | — | — | EP | disclosed |
| EP-0788526-A4 | NEGATIVE BIREFRINGENT RIGID ROD POLYMER FILMS | UNIV AKRON (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0788526-A1 | NEGATIVE BIREFRINGENT RIGID ROD POLYMER FILMS | The University of Akron (US) | 1997-08-13 | — | — | EP | disclosed |
| US-5580950-A | POLYESTERS, POLYAMIDES, POLYAMIDEIMIDE, OR POLYESTERIMIDE | THE UNIVERSITY OF AKRON (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1996011967-A1 | NEGATIVE BIREFRINGENT RIGID ROD POLYMER FILMS | THE UNIVERSITY OF AKRON (US) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UBQLN2, SOD1, UBQLN1 | SMN1; SMN2 8/4885POLB 1958/4885KDM4E 4157/4885 |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | SMN1; SMN2 179/4885POLB 693/4885KDM4E 4333/4885 |
| US-20240158364-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | NLN, UQCRC2, TUFM | SMN1; SMN2 179/4885POLB 693/4885KDM4E 4333/4885 |
| US-20240158363-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | NLN, UQCRC2, TUFM | SMN1; SMN2 179/4885POLB 693/4885KDM4E 4333/4885 |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | SMN1; SMN2 179/4885POLB 693/4885KDM4E 4333/4885 |
| US-20220259173-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | NLN, UQCRC2, TUFM | SMN1; SMN2 179/4885POLB 693/4885KDM4E 4333/4885 |
| US-20240158365-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | NLN, UQCRC2, TUFM | SMN1; SMN2 179/4885POLB 693/4885KDM4E 4333/4885 |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | SMN1; SMN2 179/4885POLB 693/4885KDM4E 4333/4885 |
| US-20240139149-A1 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | TNNT2, TNNI3, TNNC1 | SMN1; SMN2 200/4885POLB 3941/4885KDM4E 3913/4885 |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | SMN1; SMN2 179/4885POLB 693/4885KDM4E 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.